Vertex Is 1 Step Closer to Bringing a New Blockbuster to Market. Time to Buy?The Motley Fool • 04/04/23
Vertex and CRISPR Therapeutics Complete Submission of Rolling Biologics License Applications (BLAs) to the US FDA for exa-cel for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta ThalassemiaBusiness Wire • 04/03/23
This Top Growth Stock Is Targeting a Multi-Billion-Dollar Market. Here's What It Means for InvestorsThe Motley Fool • 03/31/23
Vertex and CRISPR Therapeutics Announce Licensing Agreement to Accelerate Development of Vertex's Hypoimmune Cell Therapies for the Treatment of Type 1 DiabetesBusiness Wire • 03/27/23
The Cream Of The Crop: 5 Biotech Stocks That Outrank 91% Of All StocksInvestors Business Daily • 03/24/23